Back
Goldman Sachs Nasdaq-100 Premium Income ETF Vs. Oruka Therapeutics, Inc. Industry Stock Comparison
Buy
61
GPIQ
Goldman Sachs Nasdaq-100 Premium Income ETF
Last Price:
$52.88
Seasonality Move:
-1.01%
Sell
26
ORKA
Oruka Therapeutics, Inc.
Last Price:
$30.39
Seasonality Move:
-9.32%
Buy
61
Goldman Sachs Nasdaq-100 Premium Income ETF (GPIQ)
is a Buy
Is Goldman Sachs Nasdaq-100 Premium Income ETF a Buy, Sell or Hold?
-
The current Goldman Sachs Nasdaq-100 Premium Income ETF [GPIQ] share price is $52.87. The Score for GPIQ is 61, which is 22% above its historic median score of 50, and infers lower risk than normal.
-
GPIQ is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
26
Oruka Therapeutics, Inc. (ORKA)
is a Sell
Is Oruka Therapeutics, Inc. a Buy, Sell or Hold?
-
The current Oruka Therapeutics, Inc. [ORKA] share price is $30.31. The Score for ORKA is 26, which is 48% below its historic median score of 50, and infers higher risk than normal.
-
ORKA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
GPIQ Stock Price Chart
What is Goldman Sachs Nasdaq-100 Premium Income ETF's stock price today?
-
The Goldman Sachs Nasdaq-100 Premium Income ETF share price today is $52.87The current trend is moderately bearish and GPIQ is experiencing selling pressure, which indicates risk of future bearish movement.
ORKA Stock Price Chart
What is Oruka Therapeutics, Inc.'s stock price today?
-
The Oruka Therapeutics, Inc. share price today is $30.31The current trend is moderately bullish and ORKA is experiencing slight buying pressure.
GPIQ Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.12 | Buy |
| Relative Strength Index (14 RSI): | 49.26 | Sell |
| Chaikin Money Flow: | -1255183 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (52.49 - 53.43) | Sell |
| Bollinger Bands (100): | (51.13 - 53.27) | Buy |
ORKA Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.57 | Buy |
| Relative Strength Index (14 RSI): | 51.81 | Buy |
| Chaikin Money Flow: | 234570 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (29 - 31.58) | Buy |
| Bollinger Bands (100): | (16.97 - 29.87) | Buy |
GPIQ Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 53.11 | Sell |
| 20-day SMA: | 53.01 | Sell |
| 50-day SMA: | 52.92 | Sell |
| 200-day SMA: | 49.6 | Buy |
| 8-day EMA: | 53.07 | Sell |
| 20-day EMA: | 52.95 | Sell |
| 50-day EMA: | 52.7 | Buy |
| 200-day EMA: | 50.67 | Buy |
ORKA Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 31.21 | Sell |
| 20-day SMA: | 30.53 | Sell |
| 50-day SMA: | 28.99 | Buy |
| 200-day SMA: | 17.48 | Buy |
| 8-day EMA: | 30.57 | Sell |
| 20-day EMA: | 30.26 | Buy |
| 50-day EMA: | 28.26 | Buy |
| 200-day EMA: | 21.62 | Buy |
Goldman Sachs Nasdaq-100 Premium Income ETF Earnings Growth & GPIQ Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Oruka Therapeutics, Inc. Earnings Growth & ORKA Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.18 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.32 per share, and a decrease next year of $0.42 per share.
Goldman Sachs Nasdaq-100 Premium Income ETF Technical Analysis
| Dec 16 | Dec 17 | Dec 18 | Dec 19 | Dec 22 | Dec 24 | Dec 26 | Dec 29 | Dec 30 | Dec 31 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec | ||||||||||
| 16 | 17 | 18 | 19 | 22 | 24 | 26 | 29 | 30 | 31 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Oruka Therapeutics, Inc. Technical Analysis
| Dec 17 | Dec 18 | Dec 19 | Dec 22 | Dec 23 | Dec 24 | Dec 26 | Dec 29 | Dec 30 | Dec 31 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec | ||||||||||
| 17 | 18 | 19 | 22 | 23 | 24 | 26 | 29 | 30 | 31 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||